Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Epidermolysis Bullosa
Interventions: SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more

Conditions: Degenerative Arthritis, Rheumatoid Arthritis, Post Traumatic Arthritis
Interventions: Zimmer Trabecular Metal Total Ankle System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 5
States / cities: Sacramento, California • Grand Rapids, Michigan • Charlotte, North Carolina + 2 more

Conditions: Melanoma
Interventions: Pembrolizumab, Wide Excision and Sentinel Lymph Node (SLN) Biopsy; Drug · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Louisville, Kentucky • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Breast Cancer
Interventions: 2D US grayscale plus quantitative VCEUS; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pressure Ulcers
Interventions: Sorbion Sachet S; Other
Lead sponsor: Southwest Regional Wound Care Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions: OM336; Drug
Lead sponsor: Lakefront Biotherapeutics West LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more

Conditions: Metastatic Melanoma
Interventions: 1 mg/kg GR-MD-02, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02, 8 mg/kg GR-MD-02, Ipilimumab; Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Melanoma
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Scar, Surgical Scar, Cicatrix, Cicatrix, Hypertrophic, Keloid
Interventions: 532nm KTP, 595nm PDL; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Venous Stasis Ulcers
Interventions: Revera Wound Care, Normal Saline; Device
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Foot Ulcer, Diabetic
Interventions: Medical Food, Drink mix calorically similar to experimental product; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Brawley, California + 38 more

Conditions: Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer
Interventions: Riluzole, Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Pyoderma Gangrenosum
Interventions: Deucravacitinib; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cutaneous Melanoma, Mucosal Melanoma
Interventions: Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing, Pembrolizumab; Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Uterine Leiomyoma, Uterine Fibroids
Interventions: Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 72
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
Interventions: Pazopanib, Ixabepilone; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Melanoma
Interventions: Enco+bini; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Raynaud's Disease
Interventions: placebo, diosmiplex; Other · Dietary Supplement
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Peoria, Arizona • Scottsdale, Arizona • Los Alamitos, California + 8 more

Conditions: Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie's Syndrome
Interventions: laronidase; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Los Angles, California • Hartford, Connecticut • Milwaukee, Wisconsin

Conditions: Skin Cancer
Interventions: Airbrush, Airbrush Plus, Delayed Airbrush; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 16 Years to 65 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Onychomycosis, Tinea Unguium
Interventions: Tavaborole 5% Topical Solution; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 72 Months to 203 Months
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Madera, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, sargramostim; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Malignant Melanoma
Interventions: CP-461; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions: Individualized Piano Keyboard Instruction; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Zimmer Trabecular Metal Total Ankle PMCF

Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy

Study to Evaluate the Effect of Sorbion Sachet S Wound Dressing

OM336 in Autoimmune Cytopenias

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars

Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers

Evaluation of a Medical Food for Chronic Wounds

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Deucravacitinib in PG

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Pilot Investigation of Behavioral Alternatives to Indoor Tanning

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

CP-461 in the Treatment of Patients With Advanced Melanoma

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.